HIROSHI NAGATOMO, MIEKO KAKIZAKI and KANJI TSUCHIYA Biological Research Laboratories, Central Research Division, Takeda Chemical Industries, Ltd., Osaka, Japan (Received for publication September 19, 1973) Nine laboratory standard strains and 29 clinically isolated strains of Pseudomonas aeruginosa were employed for the studies of combined use of sulbenicillin and gentamicin in vitro. Increased antibacterial activity by the combined use of the two drugs over the activity of either drug alone was observed against all the strains tested. Bactericidal activity against P. aeruginosa N 18 was enhanced by combining the two drugs. Synergistic activity of the two drugs was also observed in protective studies against intraperitoneal infection in mice by several Pseudomonas strains.
Sulbenicillin is a broad spectrum semisynthetic penicillin that possesses in vitro and in vivo antibacterial activity against Pseudomonas aeruginosa.1,2) Clinical trials indicated that sulbenicillin was a useful drug for certain Pseudomonas infections.3) Gentamicin is an aminoglycoside antibiotic which is proved to be active against Gram-positive and Gram-negative bacteria including P. aeruginosa. 4, 5) The combined use of gentamicin with several other antibiotics were studied.6,7) BRUMFITT et al.8) reported for the first time that the enhancement of antibacterial activity against P. aeruginosa was found in the combined use of carbenicillin and gentamicin. Several laboratory and clinical studies9-23) also revealed that the combined use of these two drugs was more effective against P. aeruginosa and its infections. On the other hand, McLAUGHLIN and REEVES24) reported the inactivation of gentamicin by the combined use with carbenicillin in vitro and in vivo. Many discussions have been given to these problems until today.
The present paper reports the synergistic activity of sulbenicillin and gentamicin in in vitro antibacterial studies and protective studies of combined use of the two drugs against intraperitoneal Pseudomonas infection in mice.
Materials and Methods
Antibiotics:
Disodium sulbenicillin used was a commercial sample of Takeda Chemical Industries, Ltd., Osaka, Japan.
Gentamicin sulfate in commercial grade ("Gentacin") was perchased from Schering Corporation, U.S.A. The antibiotics were dissolved in distilled water. 2. Animals: Four week old male ddy-SLC mice weighing 19-23g were used. 3. Strains: Laboratory standard strains; P. aeruginosa N 18, D 363, U 31, P 1, P 3, P 5, P 6, P 8, P 10 and NC-5 were supplied by Dr. Y. HONMA, the Institute of Medical Science, the University of Tokyo. P. aeruginosa sp. which was maintained in our laboratory for a long time was also used. Clinical isolates of P. aeruginosa were made available through the courtesy of Miss Y. SHIMIZU, the Central Clinical Laboratory, Osaka University Hospital.
4. Antibacterial studies in vitro: Antibacterial activity was determined by the agar-dilution method using Trypticase soy agar (TSA) (BBL) as test medium. The test organisms were cultivated overnight in King A* broth and the cultures were diluted 10- An overnight culture of test organism in King A broth was suspended in 103 times volume of Trypticase soy broth (TSB) (BBL), and sulbenicillin, gentamicin and combination of the two drugs were added in dose of one-half of the minimum inhibitory concentration. 6. Protective test: P. aeruginosa N 18, D 363, U 31, sp. and NC-5 cultivated overnight in King A broth were diluted to the concentration of 10-3, 10-1, 10-2, 10-2 and 10-6 with 5 % mucin, respectively. The mice were injected intraperitoneally with 0.5 ml of the bacterial suspension. Antibiotic solution was given in a single subcutaneous administration at a different site immediately after challenge. All the strains employed were susceptible to sulbenicillin and gentamicin, respectively. Susceptibilities of these organisms to two drugs are shown in Table 1 .
Results

Antibacterial Activity
In vitro susceptibility of P. aeruginosa N 18 to sulbenicillin, gentarnicin and combination of the two drugs at various concentrations is shown in Table 2 . The growth of P . aeruginosa N 18 was inhibited by sulbenicillin and gentamicin at the concentrations of 1.56 and 0.4 mcg/ml, respectively, and the organism has grown with various degree at lower concentration than that above described. However, on the medium containing 0.2 mcg/ml of gentamicin, the growth of the organism was inhibited at the concentration of 0.4 mcg/ml of sulbenicillin, and on the medium containing 0.1 mcg/ml of gentamicin, it was inhibited at the concentration of 0.78 mcg/ml of sulbenicillin. In this case, the combined action index was 3.
The combined activity of sulbenicillin and gentamicin was tested against 9 laboratory standard strains and 29 strains isolates from the clinical materials of P. aeruginosa. As shown in Tables 3 and 4 Viable ceii units (log) Hours Table 5 Since the apparent combined action of sulbenicilin and gentamicin was observed in mice infected with P. aeruginosa N 18, the combined activity of the two drugs was tested on the intraperitoneal infection in mice by several other Pseudomonas strains. Protective effect of single dose gentamicin on infected mice is shown in Table 6 . The highest dose of gentamicin which did not protect the mice infected with P. aeruginosa D 363, U 31, sp. and NC-5 was 6.25, 12.5, 12.5 and 6.25 mg/kg, respectively. These gentamicin doses were then combined with sulbenicillin.
Protective activity of the combined use of sulbenicilin and gentamicin was compared with that of the single use of sulbenicillin. Seven days after the administration, marked increase in survival rate was observed after the combined treatment of sulbenicillin and gentamicin, as shown in Fig. 3 
